Neoral
FDA Approves Dotarem, a New MRI Agent »
"The U.S. Food and Drug Administration today approved Dotarem (gadoterate meglumine) for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues of patients ages 2 years and older.
Dotarem is a gadolinium-based"...
Neoral
Neoral Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Neoral (cyclosporine) is used to prevent organ rejection after a kidney, liver, or heart transplant. It is also used to treat severe psoriasis or severe rheumatoid arthritis. It is an immunosuppressant. This medication is available in generic form. Common side effects include headache, nausea, vomiting, diarrhea, stomach upset, acne, cramps, increased hair growth on the face/body, shaking fingers/hands (tremor), swollen/red/painful gums, dizziness, flushing, and high blood pressure.
Dosing of Neroal is individualized based on the type of transplant, and the patient's weight. Neoral may interact with etoposide, lithium, methotrexate, nefazodone, repaglinide, St. John's wort, ACE inhibitors, heart or blood pressure medication, medicines used to treat ulcerative colitis, other medicines used to prevent organ transplant rejection, pain or arthritis medicines, IV antibiotics, antiviral medicines, or cancer medicine. Tell your doctor all medications and supplements you use. Neoral should be used only when prescribed during pregnancy. Cyclosporine used during pregnancy has resulted in newborns with problems such as low birth weight and being born prematurely. It has also caused death of the fetus. This medication passes into breast milk. Breast-feeding is not recommended while using this drug. Our Neoral (cyclosporine) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Neoral in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:
- urinating less than usual or not at all;
- drowsiness, confusion, mood changes, increased thirst;
- swelling, weight gain, feeling short of breath;
- blurred vision, headache or pain behind your eyes, sometimes with vomiting;
- seizure (convulsions);
- muscle pain or weakness, fast heart rate, feeling light-headed;
- signs of infection such as fever, chills, sore throat, flu symptoms;
- pale skin, easy bruising or bleeding, unusual weakness; or
- nausea, stomach pain, loss of appetite, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).
Less serious side effects may include:
- tremors or shaking;
- increased hair growth;
- headache or body pain;
- diarrhea, constipation, vomiting; or
- numbness or tingly feeling.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Neoral (Cyclosporine) »
What is Patient Information Overview?
A concise overview of the drug for the patient or caregiver from First DataBank.
Neoral Overview - Patient Information: Side Effects
Headache, nausea, vomiting, diarrhea, stomach upset, acne, cramps, increased hair growth on the face/body, shaking fingers/hands (tremor), swollen/red/painful gums, dizziness, flushing, and high blood pressure may occur. If any of these effects persist or worsen, notify your doctor or pharmacist promptly.
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Your risk of infection may be higher while you are taking this medication. Tell your doctor immediately if any of these symptoms of infection occur: fever, sore throat, flu-like symptoms, painful urination.
Tell your doctor immediately if any of these unlikely but serious side effects occur: severe muscle spasms, fast/irregular heartbeat, muscle weakness, confusion, change in the amount/color of urine, unusual weight gain/loss, tingling of the hands/feet, hearing problems, easy bruising/bleeding, unusual tiredness.
Tell your doctor immediately if any of these rare but very serious side effects occur: dark urine, persistent nausea/vomiting, severe stomach/abdominal pain, yellowing of the skin/eyes, vomit that looks like coffee grounds, change in the appearance or size of skin moles/lesions, changes in skin color, loss of consciousness, mental/mood changes, vision changes, swollen glands, unusual lumps, night sweats.
Seek immediate medical attention if any of these rare but very serious side effects occur: chest pain, seizures.
A very serious allergic reaction to this drug is unlikely, but seek immediate medical attention if it occurs. Symptoms of a serious allergic reaction include: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Read the entire patient information overview for Neoral (Cyclosporine)»
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Neoral FDA Prescribing Information: Side Effects
(Adverse Reactions)
SIDE EFFECTS
Kidney, Liver, and Heart Transplantation
The principal adverse reactions of cyclosporine therapy are renal dysfunction, tremor, hirsutism, hypertension, and gum hyperplasia.
Hypertension
Hypertension, which is usually mild to moderate, may occur in approximately 50% of patients following renal transplantation and in most cardiac transplant patients.
Glomerular Capillary Thrombosis
Glomerular capillary thrombosis has been found in patients treated with cyclosporine and may progress to graft failure. The pathologic changes resembled those seen in the hemolytic-uremic syndrome and included thrombosis of the renal microvasculature, with platelet-fibrin thrombi occluding glomerular capillaries and afferent arterioles, microangiopathic hemolytic anemia, thrombocytopenia, and decreased renal function. Similar findings have been observed when other immunosuppressives have been employed post-transplantation.
Hypomagnesemia
Hypomagnesemia has been reported in some, but not all, patients exhibiting convulsions while on cyclosporine therapy. Although magnesium-depletion studies in normal subjects suggest that hypomagnesemia is associated with neurologic disorders, multiple factors, including hypertension, high dose methylprednisolone, hypocholesterolemia, and nephrotoxicity associated with high plasma concentrations of cyclosporine appear to be related to the neurological manifestations of cyclosporine toxicity.
Clinical Studies
In controlled studies, the nature, severity, and incidence of the adverse events that were observed in 493 transplanted patients treated with Neoral® were comparable with those observed in 208 transplanted patients who received Sandimmune® in these same studies when the dosage of the two drugs was adjusted to achieve the same cyclosporine blood trough concentrations.
Based on the historical experience with Sandimmune®, the following reactions occurred in 3% or greater of 892 patients involved in clinical trials of kidney, heart, and liver transplants.
| Body System | Adverse Reactions | Randomized Kidney Patients | Cyclosporine Patients (Sandimmune®) | |||
| Sandimmune® (N=227)% |
Azathioprine (N=228)% |
Kidney (N=705)% |
Heart (N=112)% |
Liver (N=75)% |
||
| Genitourinary | Renal Dysfunction | 32 | 6 | 25 | 38 | 37 |
| Cardiovascular | Hypertension | 26 | 18 | 13 | 53 | 27 |
| Cramps | 4 | < 1 | 2 | < 1 | 0 | |
| Skin | Hirsutism | 21 | < 1 | 21 | 28 | 45 |
| Acne | 6 | 8 | 2 | 2 | 1 | |
| Central Nervous System | Tremor | 12 | 0 | 21 | 31 | 55 |
| Convulsions | 3 | 1 | 1 | 4 | 5 | |
| Headache | 2 | < 1 | 2 | 15 | 4 | |
| Gastrointestinal | Gum Hyperplasia | 4 | 0 | 9 | 5 | 16 |
| Diarrhea | 3 | < 1 | 3 | 4 | 8 | |
| Nausea/Vomiting | 2 | < 1 | 4 | 10 | 4 | |
| Hepatotoxicity Abdominal | < 1 | < 1 | 4 | 7 | 4 | |
| Discomfort | < 1 | 0 | < 1 | 7 | 0 | |
| Autonomic Nervous System | Paresthesia | 3 | 0 | 1 | 2 | 1 |
| Flushing | < 1 | 0 | 4 | 0 | 4 | |
| Hematopoietic | Leukopenia | 2 | 19 | < 1 | 6 | 0 |
| Lymphoma | < 1 | 0 | 1 | 6 | 1 | |
| Respiratory | Sinusitis | < 1 | 0 | 4 | 3 | 7 |
| Miscellaneous | Gynecomastia | < 1 | 0 | < 1 | 4 | 3 |
Among 705 kidney transplant patients treated with cyclosporine oral solution (Sandimmune®) in clinical trials, the reason for treatment discontinuation was renal toxicity in 5.4%, infection in 0.9%, lack of efficacy in 1.4%, acute tubular necrosis in 1.0%, lymphoproliferative disorders in 0.3%, hypertension in 0.3%, and other reasons in 0.7% of the patients.
The following reactions occurred in 2% or less of cyclosporine-treated patients: allergic reactions, anemia, anorexia, confusion, conjunctivitis, edema, fever, brittle fingernails, gastritis, hearing loss, hiccups, hyperglycemia, migraine (Neoral®) muscle pain, peptic ulcer, thrombocytopenia, tinnitus.
The following reactions occurred rarely: anxiety, chest pain, constipation, depression, hair breaking, hematuria, joint pain, lethargy, mouth sores, myocardial infarction, night sweats, pancreatitis, pruritus, swallowing difficulty, tingling, upper GI bleeding, visual disturbance, weakness, weight loss.
Patients receiving immunosuppressive therapies, including cyclosporine and cyclosporine -containing regimens, are at increased risk of infections (viral, bacterial, fungal, parasitic). Both generalized and localized infections can occur. Pre-existing infections may also be aggravated. Fatal outcomes have been reported. (see WARNINGS)
Infectious Complications in Historical Randomized Studies
in Renal Transplant Patients Using Sandimmune®
| Complication | Cyclosporine Treatment (N=227) % of Complications |
Azathioprine with Steroids* (N=228) % of Complications |
| Septicemia | 5.3 | 4.8 |
| Abscesses | 4.4 | 5.3 |
| Systemic Fungal Infection | 2.2 | 3.9 |
| Local Fungal Infection | 7.5 | 9.6 |
| Cytomegalovirus | 4.8 | 12.3 |
| Other Viral Infections | 15.9 | 18.4 |
| Urinary Tract Infections | 21.1 | 20.2 |
| Wound and Skin Infections | 7.0 | 10.1 |
| Pneumonia | 6.2 | 9.2 |
| *Some patients also received ALG. | ||
Postmarketing Experience, Kidney, Liver and Heart Transplantation
Hepatotoxicity
Cases of hepatotoxicity and liver injury including cholestasis, jaundice, hepatitis and liver failure; serious and/or fatal outcomes have been reported. [See WARNINGS/Hepatotoxicity]
Increased Risk of Infections
Cases of JC virus-associated progressive multifocal leukoencephalopathy (PML), sometimes fatal; and polyoma virus-associated nephropathy (PVAN), especially BK virus resulting in graft loss have been reported. [See WARNINGS/ Polyoma Virus Infection]
Headache, including Migraine
Cases of migraine have been reported. In some cases, patients have been unable to continue cyclosporine, however, the final decision on treatment discontinuation should be made by the treating physician following the careful assessment of benefits versus risks.
The principal adverse reactions associated with the use of cyclosporine in rheumatoid arthritis are renal dysfunction (see WARNINGS), hypertension (see PRECAUTIONS), headache, gastrointestinal disturbances, and hirsutism/hypertrichosis.
In rheumatoid arthritis patients treated in clinical trials within the recommended dose range, cyclosporine therapy was discontinued in 5.3% of the patients because of hypertension and in 7% of the patients because of increased creatinine. These changes are usually reversible with timely dose decrease or drug discontinuation. The frequency and severity of serum creatinine elevations increase with dose and duration of cyclosporine therapy. These elevations are likely to become more pronounced without dose reduction or discontinuation.
The following adverse events occurred in controlled clinical trials:
Neoral®/Sandimmune® Rheumatoid Arthritis Percentage of Patients with Adverse Events ≥ 3%
in any Cyclosporine Treated Group
| Body System Preferred Term |
Studies 651+652+2008 | Study 302 | Study 654 | Study 654 | Study 302 | Studies 651+652+2008 |
| Sandimmune®† (N=269) |
Sandimmune® (N=155) |
Methotrexate & Sandimmune® (N=74) |
Methotrexate & Placebo (N=73) |
Neoral® (N=143) |
Placebo (N=201) |
|
| Autonomic Nervous System Disorders | ||||||
| Flushing | 2% | 2% | 3% | 0% | 5% | 2% |
| Body As A Whole-General Disorders | ||||||
| Accidental Trauma | 0% | 1% | 10% | 4% | 4% | 0% |
| Edema NOS* | 5% | 14% | 12% | 4% | 10% | < 1% |
| Fatigue | 6% | 3% | 8% | 12% | 3% | 7% |
| Fever | 2% | 3% | 0% | 0% | 2% | 4% |
| Influenza-like symptoms | < 1% | 6% | 1% | 0% | 3% | 2% |
| Pain | 6% | 9% | 10% | 15% | 13% | 4% |
| Rigors | 1% | 1% | 4% | 0% | 3% | 1% |
| Cardiovascular Disorders | ||||||
| Arrhythmia | 2% | 5% | 5% | 6% | 2% | 1% |
| Chest Pain | 4% | 5% | 1% | 1% | 6% | 1% |
| Hypertension | 8% | 26% | 16% | 12% | 25% | 2% |
| Central and Peripheral Nervous System Disorders | ||||||
| Dizziness | 8% | 6% | 7% | 3% | 8% | 3% |
| Headache | 17% | 23% | 22% | 11% | 25% | 9% |
| Migraine | 2% | 3% | 0% | 0% | 3% | 1% |
| Paresthesia | 8% | 7% | 8% | 4% | 11% | 1% |
| Tremor | 8% | 7% | 7% | 3% | 13% | 4% |
| Gastrointestinal System Disorders | ||||||
| Abdominal Pain | 15% | 15% | 15% | 7% | 15% | 10% |
| Anorexia | 3% | 3% | 1% | 0% | 3% | 3% |
| Diarrhea | 12% | 12% | 18% | 15% | 13% | 8% |
| Dyspepsia | 12% | 12% | 10% | 8% | 8% | 4% |
| Flatulence | 5% | 5% | 5% | 4% | 4% | 1% |
| Gastrointestinal Disorder NOS* | 0% | 2% | 1% | 4% | 4% | 0% |
| Gingivitis | 4% | 3% | 0% | 0% | 0% | 1% |
| Gum Hyperplasia | 2% | 4% | 1% | 3% | 4% | 1% |
| Nausea | 23% | 14% | 24% | 15% | 18% | 14% |
| Rectal Hemorrhage | 0% | 3% | 0% | 0% | 1% | 1% |
| Stomatitis | 7% | 5% | 16% | 12% | 6% | 8% |
| Vomiting | 9% | 8% | 14% | 7% | 6% | 5% |
| Hearing and Vestibular Disorders | ||||||
| Ear Disorder NOS* | 0% | 5% | 0% | 0% | 1% | 0% |
| Metabolic and Nutritional Disorders | ||||||
| Hypomagnesemia | 0% | 4% | 0% | 0% | 6% | 0% |
| Musculoskeletal System Disorders | ||||||
| Arthropathy Leg Cramps / Involuntary | 0% | 5% | 0% | 1% | 4% | 0% |
| Muscle Contractions | 2% | 11% | 11% | 3% | 12% | 1% |
| Psychiatric Disorders | ||||||
| Depression | 3% | 6% | 3% | 1% | 1% | 2% |
| Insomnia | 4% | 1% | 1% | 0% | 3% | 2% |
| Renal | ||||||
| Creatinine elevations ≥ 30% | 43% | 39% | 55% | 19% | 48% | 13% |
| Creatinine elevations ≥ 50% | 24% | 18% | 26% | 8% | 18% | 3% |
| Reproductive Disorders, Female | ||||||
| Leukorrhea | 1% | 0% | 4% | 0% | 1% | 0% |
| Menstrual Disorder | 3% | 2% | 1% | 0% | 1% | 1% |
| Respiratory System Disorders | ||||||
| Bronchitis | 1% | 3% | 1% | 0% | 1% | 3% |
| Coughing | 5% | 3% | 5% | 7% | 4% | 4% |
| Dyspnea | 5% | 1% | 3% | 3% | 1% | 2% |
| Infection NOS* | 9% | 5% | 0% | 7% | 3% | 10% |
| Pharyngitis | 3% | 5% | 5% | 6% | 4% | 4% |
| Pneumonia | 1% | 0% | 4% | 0% | 1% | 1% |
| Rhinitis | 0% | 3% | 11% | 10% | 1% | 0% |
| Sinusitis | 4% | 4% | 8% | 4% | 3% | 3% |
| Upper Respiratory Tract | 0% | 14% | 23% | 15% | 13% | 0% |
| Skin and Appendages Disorders | ||||||
| Alopecia | 3% | 0% | 1% | 1% | 4% | 4% |
| Bullous Eruption | 1% | 0% | 4% | 1% | 1% | 1% |
| Hypertrichosis | 19% | 17% | 12% | 0% | 15% | 3% |
| Rash | 7% | 12% | 10% | 7% | 8% | 10% |
| Skin Ulceration | 1% | 1% | 3% | 4% | 0% | 2% |
| Urinary System Disorders | ||||||
| Dysuria | 0% | 0% | 11% | 3% | 1% | 2% |
| Micturition Frequency | 2% | 4% | 3% | 1% | 2% | 2% |
| NPN, Increased | 0% | 19% | 12% | 0% | 18% | 0% |
| Urinary Tract Infection | 0% | 3% | 5% | 4% | 3% | 0% |
| Vascular (Extracardiac) Disorders | ||||||
| Purpura | 3% | 4% | 1% | 1% | 2% | 0% |
| † Includes patients in 2.5
mg/kg/day dose group only. *NOS = Not Otherwise Specified. |
||||||
In addition, the following adverse events have been reported in 1% to < 3% of the rheumatoid arthritis patients in the cyclosporine treatment group in controlled clinical trials.
Autonomic Nervous System: dry mouth, increased sweating;
Body as a Whole: allergy, asthenia, hot flushes, malaise, overdose, procedure NOS*, tumor NOS*, weight decrease, weight increase;
Cardiovascular: abnormal heart sounds, cardiac failure, myocardial infarction, peripheral ischemia;
Central and Peripheral Nervous System:hypoesthesia, neuropathy, vertigo;
Endocrine: goiter;
Gastrointestinal: constipation, dysphagia, enanthema, eructation, esophagitis, gastric ulcer, gastritis, gastroenteritis, gingival bleeding, glossitis, peptic ulcer, salivary gland enlargement, tongue disorder, tooth disorder;
Infection: abscess, bacterial infection, cellulitis, folliculitis, fungal infection, herpes simplex, herpes zoster, renal abscess, moniliasis, tonsillitis, viral infection;
Hematologic: anemia, epistaxis, leukopenia, lymphadenopathy;
Liver and Biliary System: bilirubinemia;
Metabolic and Nutritional: diabetes mellitus, hyperkalemia, hyperuricemia, hypoglycemia;
Musculoskeletal System: arthralgia, bone fracture, bursitis, joint dislocation, myalgia, stiffness, synovial cyst, tendon disorder;
Neoplasms: breast fibroadenosis, carcinoma;
Psychiatric: anxiety, confusion, decreased libido, emotional lability, impaired concentration, increased libido, nervousness, paroniria, somnolence;
Reproductive (Female): breast pain, uterine hemorrhage;
Respiratory System: abnormal chest sounds, bronchospasm;
Skin and Appendages: abnormal pigmentation, angioedema, dermatitis, dry skin, eczema, nail disorder, pruritus, skin disorder, urticaria;
Special Senses: abnormal vision, cataract, conjunctivitis, deafness, eye pain, taste perversion, tinnitus, vestibular disorder;
Urinary System: abnormal urine, hematuria, increased BUN, micturition urgency, nocturia, polyuria, pyelonephritis, urinary incontinence.
*NOS = Not Otherwise Specified.
Psoriasis
The principal adverse reactions associated with the use of cyclosporine in patients with psoriasis are renal dysfunction, headache, hypertension, hypertriglyceridemia, hirsutism/hypertrichosis, paresthesia or hyperesthesia, influenza-like symptoms, nausea/vomiting, diarrhea, abdominal discomfort, lethargy, and musculoskeletal or joint pain.
In psoriasis patients treated in US controlled clinical studies within the recommended dose range, cyclosporine therapy was discontinued in 1.0% of the patients because of hypertension and in 5.4% of the patients because of increased creatinine. In the majority of cases, these changes were reversible after dose reduction or discontinuation of cyclosporine.
There has been one reported death associated with the use of cyclosporine in psoriasis. A 27-year-old male developed renal deterioration and was continued on cyclosporine. He had progressive renal failure leading to death.
Frequency and severity of serum creatinine increases with dose and duration of cyclosporine therapy. These elevations are likely to become more pronounced and may result in irreversible renal damage without dose reduction or discontinuation.
Adverse Events Occurring in 3%
or More of Psoriasis Patients in Controlled Clinical Trials
| Body System* | Preferred Term | Neoral® (N=182) |
Sandimmune® (N=185) |
| Infection or Potential Infection | 24.7% | 24.3% | |
| Influenza-Like Symptoms | 9.9% | 8.1% | |
| Upper Respiratory Tract Infections | 7.7% | 11.3% | |
| Cardiovascular System | 28.0% | 25.4% | |
| Hypertension** | 27.5% | 25.4% | |
| Urinary System | 24.2% | 16.2% | |
| Increased Creatinine | 19.8% | 15.7% | |
| Central and Peripheral Nervous System | 26.4% | 20.5% | |
| Headache | 15.9% | 14.0% | |
| Paresthesia | 7.1% | 4.8% | |
| Musculoskeletal System | 13.2% | 8.7% | |
| Arthralgia | 6.0% | 1.1% | |
| Body As a Whole-General | 29.1% | 22.2% | |
| Pain | 4.4% | 3.2% | |
| Metabolic and Nutritional | 9.3% | 9.7% | |
| Reproductive, Female | 8.5% (4 of 47 females) | 11.5% (6 of 52 females) | |
| Resistance Mechanism | 18.7% | 21.1% | |
| Skin and Appendages | 17.6% | 15.1% | |
| Hypertrichosis | 6.6% | 5.4% | |
| Respiratory System | 5.0% | 6.5% | |
| Bronchospasm, Coughing, Dyspnea, Rhinitis | 5.0% | 4.9% | |
| Psychiatric | 5.0% | 3.8% | |
| Gastrointestinal System | 19.8% | 28.7% | |
| Abdominal Pain | 2.7% | 6.0% | |
| Diarrhea | 5.0% | 5.9% | |
| Dyspepsia | 2.2% | 3.2% | |
| Gum Hyperplasia | 3.8% | 6.0% | |
| Nausea | 5.5% | 5.9% | |
| White cell and RES | 4.4% | 2.7% | |
| *Total percentage of events within the system **Newly occurring hypertension = SBP ≥ 160 mm Hg and/or DBP ≥ 90 mm Hg |
|||
The following events occurred in 1% to less than 3% of psoriasis patients treated with cyclosporine:
Body as a Whole: fever, flushes, hot flushes;
Cardiovascular: chest pain;
Central and Peripheral Nervous System:appetite increased, insomnia, dizziness, nervousness, vertigo;
Gastrointestinal: abdominal distention, constipation, gingival bleeding;
Liver and Biliary System: hyperbilirubinemia;
Neoplasms: skin malignancies [squamous cell (0.9%) and basal cell (0.4%) carcinomas];
Reticuloendothelial: platelet, bleeding, and clotting disorders, red blood cell disorder;
Respiratory: infection, viral and other infection;
Skin and Appendages: acne, folliculitis, keratosis, pruritus, rash, dry skin;
Urinary System: micturition frequency;
Vision: abnormal vision.
Mild hypomagnesemia and hyperkalemia may occur but are asymptomatic. Increases in uric acid may occur and attacks of gout have been rarely reported. A minor and dose related hyperbilirubinemia has been observed in the absence of hepatocellular damage. Cyclosporine therapy may be associated with a modest increase of serum triglycerides or cholesterol. Elevations of triglycerides ( > 750 mg/dL) occur in about 15% of psoriasis patients; elevations of cholesterol ( > 300 mg/dL) are observed in less than 3% of psoriasis patients. Generally these laboratory abnormalities are reversible upon dose reduction or discontinuation of cyclosporine.
Read the entire FDA prescribing information for Neoral (Cyclosporine) »
Additional Neoral Information
Neoral - User Reviews
Neoral User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Here is a collection of user reviews for the medication Neoral sorted by most helpful.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
